Immune Design is an oncology-focused clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Immune Design has engineered their technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Their primary product candidate, G100, utilizes a distinct immuno-oncology approach that addresses the shortcomings of existing therapies and has the potential to treat a broad patient population. NASDAQ: IMDZ